利塞膦酸盐抗男性骨质疏松性骨折的效应

目的系统评价利塞膦酸盐对男性骨质疏松的抗骨折效应。方法通过Medline数据库、EMBASE数据库、Cochrane图书馆和中国生物医学文献数据库检索1980-01至2006-12有关利塞膦酸盐与安慰剂治疗男性骨质疏松患者的随机对照试验。随访大于12个月,提供骨折发生率的文献纳入研究。分析入选文献的方法学质量,提取资料,用RevMan4.2软件进行荟萃分析。结果3篇文献符合纳入标准,包括780例男性骨质疏松患者。荟萃分析结果显示利塞膦酸盐可降低69%的椎体骨折风险(RR=0.31,95%CI:0.16,0.60)和58%的非椎体骨折风险(RR=0.42,95%CI:0.23,0.78)。结论利塞膦酸盐对男性骨质疏松症患者可提供良好的抗骨折效应。

Anti-fracture efficacy of risedronate in men with osteoporosis: a meta-analysis

ObjectiveTo systematically assess the anti-fracture efficacy of risedronate in men with osteoporosis.MethodsRandomized controlled trials in men receiving risedronate or placebo for osteoporosis were searched from Medline, Embase, Cochrane Controlled Trial Registry and China Biological Medicine database between January, 1980 and December, 2005. We selected articles with a follow-up of at least 12 months and providing the incidence of fractures. The methodological quality of all eligible articles was independently assessed. Data from three trails were extracted and pooled. The analyses of the available data using the Revman 4.2 software were based on the intention-to-treat principle.ResultsThree trials, which included 780 men with primary or secondary osteoporosis, met all our inclusion criteria. The relative risk (RR) of vertebral and non-vertebral fractures were 0.31[95% confidence intervals (CI) 0.16, 0.60] and 0.42[95%CI 0.23, 0.78] respectively. Compared with placebo, risedronate reduced the risk of vertebral fractures by 69%(P=0.0005) and the risk of non-vertebral fractures by 58%(P=0.005).ConclusionResults of meta-analysis demonstrated that risedronate provides favorable anti-fracture efficacy in men with osteoporosis.